Currently for AD treatment, four medicines are accessible to the market, and three are cholinesterase inhibitors, including rivastigmine, memantine, galantamine, and donepezil, which act as antagonists of N-methyl-D-aspartate (NMDA) receptor [3]. Here, BCHE is linked to Alzheimer disease.